Real-time tracking of drug binding to influenza A M2 reveals a high energy barrier
Kumar Tekwani Movellan1, Melanie Wegstroth1, Kerstin Overkamp1
1Department of NMR Based Structural Biology, Max Planck Institute for Multidisciplinary Sciences, Am Fassberg 11, Göttingen, Germany.
Abstract:
The drug Rimantadine binds to two different sites in the M2 protein from influenza A, a peripheral site and a pore site that is the primary site of efficacy. It remained enigmatic that pore binding did not occur in certain detergent micelles, and in particular incomplete binding was observed in a mixture of lipids selected to match the viral membrane. Here we show that two effects are responsible, namely changes in the protein upon pore binding that prevented detergent solubilization, and slow binding kinetics in the lipid samples. Using 55-100 kHz magic-angle spinning NMR, we characterize kinetics of drug binding in three different lipid environments: DPhPC, DPhPC with cholesterol and viral mimetic membrane lipid bilayers. Slow pharmacological binding kinetics allowed the characterization of spectral changes associated with non-specific binding to the protein periphery in the kinetically trapped pore-apo state. Resonance assignments were determined from a set of proton-detected 3D spectra. Chemical shift changes associated with functional binding in the pore of M2 were tracked in real time in order to estimate the activation energy. The binding kinetics are affected by pH and the lipid environment and in particular cholesterol. We found that the imidazole-imidazole hydrogen bond at residue histidine 37 is a stable feature of the protein across several lipid compositions. Pore binding breaks the imidazole-imidazole hydrogen bond and limits solubilization in DHPC detergent.
Insights
Rimantadine binding to the influenza A M2 protein pore is hindered by slow kinetics and protein structural changes. Cholesterol and pH significantly impact drug binding within viral lipid environments.
Area of Science:
- Biophysics
- Structural Biology
- Virology
Background:
- Rimantadine targets the M2 protein pore of influenza A, crucial for viral efficacy.
- Incomplete drug binding was observed in specific lipid environments, posing a challenge to understanding its mechanism.
Purpose of the Study:
- Investigate the reasons behind incomplete Rimantadine pore binding in lipid bilayers.
- Characterize the kinetics and environmental factors influencing drug-M2 protein interactions.
Main Methods:
- Utilized 55-100 kHz magic-angle spinning NMR to study drug binding kinetics.
- Analyzed binding in three distinct lipid environments: DPhPC, DPhPC with cholesterol, and viral mimetic bilayers.
- Determined resonance assignments and tracked chemical shift changes in real-time.
Main Results:
- Identified slow binding kinetics and protein structural changes as key factors limiting pore binding.
- Demonstrated that cholesterol and pH significantly affect Rimantadine binding kinetics.
- Observed that pore binding disrupts the histidine 37 imidazole-imidazole hydrogen bond, impacting M2 protein solubilization.
Conclusions:
- Slow binding kinetics and lipid environment, particularly cholesterol, influence Rimantadine efficacy.
- Understanding these interactions is vital for developing effective influenza A antivirals.
- The M2 protein's structural dynamics play a critical role in drug binding and viral function.
Related Concept Videos
Leaky Scanning
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Drug Distribution: Plasma Protein Binding


